Pulmonx Corp (LUNG) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Pulmonx Corp's filing signal turned negative.

Pulmonx Corporation is a commercial-stage medical technology company focused on providing a minimally invasive treatment for patients suffering from severe emphysema, a form of COPD. Its core solution includes the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System, and the LungTraX Platform, designed for patients who remain symptomatic despite medical management and are not candidates for surgery. The Zephyr Valve, which received FDA pre-market approval in 2018, is commercially available globally and has established reimbursement in key markets. Pulmonx also manufactures the AeriSeal System, a synthetic polymer foam for occluding collateral air channels, which has received FDA Breakthrough Device designation and CE Mark in Europe, and is currently undergoing clinical trials to support a PMA application. The company generates most of its revenue from Zephyr Valves and delivery catheters, with a direct sales force in the U.S. and a mix of direct and distributor sales internationally.

Revenue is primarily driven by the sale of Zephyr Valves and delivery catheters. Smaller revenue streams are generated from the Chartis System (balloon catheters, usage fees, console sales) and the LungTraX Platform.